Skip to main content

Table 4 Sensitivity analysis: results of the regression analysis taking into account discontinuation of biologics on achieving remission, when this was maintained for at least 6 months

From: Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry

 

Bivariable

Multivariable

Variable

OR

95% CI

P-value

OR

95% CI

P-value

Female sex

0.59

(0.35–1.02)

0.060

0.52

(0.28–0.97)

0.039

TNF-i

1.76

(0.83–3.75)

0.143

0.99

(0.41–2.37)

0.977

Disease (ref RA)

AS

1.35

(0.66–2.74)

0.407

1.11

(0.45–2.73)

0.820

PsA

1.94

(1.04–3.60)

0.036

1.51

(0.74–3.07)

0.256

Smoking (ref smoker)

Non-smoker

3.77

(1.35–10.51)

0.011

4.34

(1.53–12.28)

0.006

Ex-smoker

0.53

(0.06–4.74)

0.596

0.64

(0.07–5.83)

0.691

Second-line treatment

1.06

(0.61–1.84)

0.831

1.65

(0.91–3.00)

0.100

Corticosteroids

0.70

(0.37–1.33)

0.273

-

-

-

Concomitant treatment

0.87

(0.50–1.50)

0.619

0.89

(0.48–1.63)

0.707

Moderate-high activitya

0.38

(0.12–1.25)

0.113

-

-

-

Age at diagnosis

1.00

(0.98–1.02)

0.663

-

-

-

Age at onset

0.99

(0.97–1.01)

0.425

1.01

(0.98–1.03)

0.530

Disease duration

0.96

(0.92–1.00)

0.052

0.94

(0.89–0.98)

0.010

Charlson Comorbidity Index

0.96

(0.79–1.17)

0.677

-

-

-

Time in treatment

1.01

(1.01–1.02)

0.001

1.01

(1.01–1.02)

 < 0.001

Year of discontinuation of treatment

1.00

(0.94–1.06)

0.991

0.99

(0.92–1.06)

0.712

  1. OR Odds ratio, 95% CI 95% confidence interval, TNF-i Tumor necrosis factor alfa inhibitor, RA Rheumatoid arthritis, AS Ankylosing spondylitis, PsA Psoriatic arthritis, RF Rheumatoid factor, ACPA Anti-citrullinated peptide antibody
  2. aModerate-high activity was defined as DAS28 ≥ 3.2 or BASDAI ≥ 4 depending on the disease